26/10/2014 03:43:42 Free Membership Login

Perceptive Informatics® Global Survey Results Show Significant Adoption of Web-based RTSM Systems by Clinical Sites

Date : 03/14/2012 @ 6:00AM
Source : PR Newswire (US)
Stock : Parexel International Corp. (MM) (PRXL)
Quote : 63.75  0.25 (0.39%) @ 8:10PM
Parexel share price Chart

Perceptive Informatics® Global Survey Results Show Significant Adoption of Web-based RTSM Systems by Clinical Sites

Parexel (NASDAQ:PRXL)
Historical Stock Chart

3 Years : From Oct 2011 to Oct 2014

Click Here for more Parexel Charts.

BOSTON, March 14, 2012 /PRNewswire/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of its Randomization and Trial Supply Management (RTSM) Survey, which tracked the evolving use of RTSM technologies, also known as Interactive Voice and Web Response Systems (IVRS/IWRS), by investigative sites worldwide. The survey polled professionals at nearly 300 investigative sites across the Americas, Europe and Asia. Results revealed a significant level of adoption of web- over voice-based versions of these technologies.

Used to randomize patients for study enrollment and manage various aspects of trial management, web-based RTSM systems provide investigative sites with the ability to collect and report on study data in real-time. According to the Perceptive Informatics analysis, this increased efficiency has provided a competitive advantage to sites in the selection process of clinical trial sponsors, who are seeking faster patient enrollment and a track record of high performance for global studies.

The Perceptive Informatics analysis showed that 65% of respondents worldwide use web-based RTSM systems to support clinical study execution. The Asia/Pacific region led all other geographies with the highest use of web- over voice-based systems, followed by Europe. In terms of the type of environment, 68% of hospital-based clinics and 61% of physician-based sites prefer web-based systems.  According to the Perceptive Informatics survey, the top three reasons cited by respondents for their preference of web-based RTSM technologies include ease of use, speed, and convenience.  Main uses of web-based RTSM technologies among investigative sites include drug accountability, identifying missing or damaged medication, and making dose adjustments.

"Sponsors are seeking to drive continuous process improvement in their clinical trial programs, and we have developed our eClinical solutions to support this goal.  The results of this study are consistent with our commitment to advance flexible, web-based RTSM technologies," said Nick Richards, Vice President, Product Development, Perceptive Informatics. "We are focused on empowering investigative sites to improve their performance.  By harnessing the power of web-based RTSM technology, sites can simplify their workflows and conduct study management activities more efficiently."

The ClinPhone® RTSM service from Perceptive Informatics offers validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities, and real-time supply reporting. The solutions provide sophisticated reporting to monitor trial management performance, trending and forecasting information, and in-depth data analysis. Clinical trials worldwide can be supported in multiple languages through the solutions, which provide secure access, a detailed audit trail, transaction logging, and compliance with FDA 21 CFR Part 11.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO).  The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, ClinPhone is a registered trademark of ClinPhone Limited, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts:

 

Jennifer Baird, Senior Director of Public Relations

Kim Leadley/Gene Carozza

PAREXEL International

PAN Communications

Tel: +781-434-4409

Tel: + 617-502-4300

Email: Jennifer.Baird@PAREXEL.com

Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation

Copyright 2012 PR Newswire



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 141026 03:43